Opaleye Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Opaleye Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-125,000	Closed	-$2.55M	–	50
2016 Q2	$2.55M	Hold	125,000	–	–	1.7%	22
2016 Q1	$1.91M	Sell	125,000 -295,000	-70%	-$3.85M	1.19%	32
2015 Q4	$5.64M	Sell	420,000 -40,000	-9%	-$619K	2.36%	19
2015 Q3	$6.45M	Sell	460,000 -75,000	-14%	-$1.39M	3.18%	11
2015 Q2	$9.08M	Hold	535,000	–	–	3.61%	8
2015 Q1	$6.47M	Buy	535,000 +185,000	+53%	+$1.75M	3%	12
2014 Q4	$2.9M	Buy	+350,000	New	+$2.94M	1.47%	26

Other funds holding SUPN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

RIM

Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Opaleye Management's SUPN Position: Q3 2016 in Review

Opaleye Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2016, closing a stake of 125,000 shares — an estimated $2.55M sold.

Opaleye Management first reported a position in SUPN in Q4 2014 and held it in 7 quarters. The position peaked at $9.08M in Q2 2015. 222 funds tracked by Wall St. Rank hold SUPN as of Q3 2016.

Opaleye Management reported no remaining Supernus Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Opaleye Management sold 125,000 Supernus Pharmaceuticals shares in Q3 2016, an estimated $2.55M.
Opaleye Management first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 7 quarters.
Opaleye Management's Supernus Pharmaceuticals position peaked at $9.08M in Q2 2015.
222 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2016.

Based on Opaleye Management's 13F filing for Q3 2016, filed 14 Nov 2016.